Investors of Capricor Therapeutics Urged to Join Securities Fraud Lawsuit
Capricor Therapeutics: Important Update for Investors
In recent developments, Rosen Law Firm, a globally recognized advocate for investor rights, has brought attention to Capricor Therapeutics, Inc. (NASDAQ: CAPR). The firm is reminding those who purchased Capricor securities between October 9, 2024, and July 10, 2025, of a critical deadline on September 15, 2025, for joining a potential securities fraud lawsuit.
Key Reasons to Take Action
Investors who incurred losses exceeding $100,000 during the specified period should consider participating in this class action. By doing so, they could be entitled to compensation without needing to pay any upfront fees through a contingency fee arrangement. This means that legal fees would be covered by the settlement amount if successful, easing the financial burden on participants.
How to Get Involved
To become part of the Capricor class action, individuals can visit Rosen Law Firm's website or contact attorney Phillip Kim at 866-767-3653. Those interested in serving as lead plaintiffs must file their motion with the court by the deadline to ensure representation.
What the Lawsuit Claims
The lawsuit arises from allegations that, throughout the class period, Capricor's executives misled investors regarding the risks and efficacy related to their lead drug candidate, deramiocel. Market confidence was largely built on seemingly positive assertions about the drug's potential to receive a Biologics License Application (BLA) from the U.S. FDA. However, the company allegedly concealed crucial safety and efficacy data from its Phase 2 HOPE-2 trial, which, if disclosed, might have deterred investment.
In essence, as a result of these misleading assertions, investors purchased Capricor's securities at inflated prices, only to face significant losses when the truth about the drug’s performance came to light.
The Importance of Choosing the Right Legal Representation
Rosen Law Firm emphasizes the significance of selecting proficient legal counsel. Many firms proposed in such notices lack the credentials and successful track records essential for navigating securities fraud cases. Rosen Law Firm has a proven history of favorable outcomes in securities litigation and has been ranked at the forefront of law firms helping investors recover losses over the years.
Rosen Law Firm made headlines in 2019 by securing over $438 million for their clients and continues to maintain a reputation as a trustworthy advocate for investors globally.
Next Steps for Investors
It is important to note that as of now, no class has been certified. Therefore, potential participants are not represented by counsel unless they actively retain one. Individuals may also choose to remain absent class members if they prefer not to take action at this time.
Finally, Rosen Law Firm encourages investors to stay informed about their rights and updates regarding this case through their social media platforms, including LinkedIn and Twitter.
For any inquiries, contact:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
Email: [email protected]
Website: www.rosenlegal.com
Smart decisions today can lead to substantial recoveries tomorrow.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.